‘If you sail a massive liner across the Atlantic, you are going to have to make at least one course correction.’ This was the analogy used by professor Jonathan Van-Tam, the UK’s deputy chief medical officer, when explaining why the UK has opted to change its approach to vaccinating healthy 18 to 29-year-olds. For this group, officials argue, there is no point in taking any risk whatsoever, no matter how negligible, and that instead they should be offered the Pfizer-BioNTech or Moderna vaccines instead of Oxford-AstraZeneca.
What we need now is urgent action to re-vitalise vaccine confidence
On the one hand, from a clinical perspective, this seems very reasonable — why take any risks if there is a better choice available? But managing pandemics isn’t just about making course corrections to navigate around the currents of clinical risk. It’s also about understanding how to strategically work with the public, to build trust that motivates them, and to foresee how their perceptions might impact upon their choices.

Get Britain's best politics newsletters
Register to get The Spectator's insight and opinion straight to your inbox. You can then read two free articles each week.
Already a subscriber? Log in
Comments
Join the debate for just $5 for 3 months
Be part of the conversation with other Spectator readers by getting your first three months for $5.
UNLOCK ACCESS Just $5 for 3 monthsAlready a subscriber? Log in